FDA Approves Moderna's RSV Vaccine for Seniors
TL;DR Summary
The FDA has approved Moderna's RSV vaccine, mResvia, for adults aged 60 and older, marking the company's second licensed product. The vaccine, which uses the same mRNA platform as Moderna's Covid-19 vaccine, showed an efficacy of 83.7% in trials and had no serious safety concerns. This approval follows the earlier market entry of RSV vaccines from GSK and Pfizer. The CDC's Advisory Committee on Immunization Practices will next review the vaccine for recommendations.
- FDA approves Moderna's RSV vaccine, its second licensed product STAT
- FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product CNBC
- FDA approves Moderna’s mRNA RSV vaccine for older adults CNN
- Moderna's RSV shot wins FDA approval for use in older adults The Seattle Times
- Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 4 min read
Condensed
91%
799 → 73 words
Want the full story? Read the original article
Read on STAT